Please login to the form below

Not currently logged in

Excellence in Healthcare Professional Education and Support Programmes

Sponsored by

Back to Results

Highly Commended

CLEAR HORIZONS: A New Era of Psoriasis Care

by AbbVie with support from Lucid Group

Summary of work

Despite recent advances in the understanding of psoriasis and rapid expansion in treatment options available, most patients with moderate‐to‐severe psoriasis still receive delayed, inadequate or suboptimal treatment. The introduction of a new class of therapies, IL‐23 inhibitors, has the potential to provide long-term efficacy beyond that currently achieved in clinical practice. CLEAR HORIZONS was designed to help physicians to understand the potential of this new treatment class and to introduce SKYRIZI (risankizumab), a new IL‐23 inhibitor.

The first phase of CLEAR HORIZONS was to establish and mobilise ’leaders of change’, a connected and empowered group of global and local innovators who would inspire change in others. An immersive delegate journey of local and global touch points led to an experiential event that would ensure ’leaders of change’ were prepared and committed to driving change and creating momentum in their countries via an omnichannel implementation strategy. Detailed partnership planning at an affiliate level established personal development journeys for all priority stakeholders aligned to an advocacy ladder and a co‐ordinated approach to metrics capture is already showing demonstrable change as a result of the programme (still in Phase 1 of a three‐year plan).

Judges' comments

CLEAR HORIZONS was an excellent entry and the judges thought it was exceptionally strong. It had great insights at the global level and clearly showed the position of patients. It made good use of the innovation model and had robust learnings.


Angels Initiative - by Boehringer Ingelheim International GmbH

Highly commended

CLEAR HORIZONS: A New Era of Psoriasis Care - by AbbVie with support from Lucid Group

Highly commended

Academy for Science and Continuing Medical Education in Diabetes (ASCEND) - by Novo Nordisk [unrestricted grant provider] with support from International Medical Press, a Nucleus Global agency


INSPIRE: Improving Outcomes in Paediatric Cardiology - by AbbVie with support from Lucid Group

4 Sites: Navigating the Course Ahead - by AbbVie with support from Sciterion

Advanced Communication Training for Heart Failure Nurses - by Novartis with support from Aurora

Key dates

Entry deadline 26 August 2022
Extended entry deadline 2 September 2022*
*additional fee applies
Judging Day 6 October 2022
Company/Team of the Year Interviews 21 October 2022
PMEA Event 23 November 2022